Current Coverage
Current Target Coverage
| PPI Target | Cancer Relevance | Interface Status | Availability |
|---|---|---|---|
| MDM2 / p53 | ~50% of human tumors; p53 pathway driver | Fully characterized | Available |
| BCL-2 / BAX interface | Apoptotic resistance, hematologic malignancies | Fully characterized | Available |
| BCL-xL / BAK | Broad apoptotic resistance across solid tumors | Characterized | Available |
| KRAS / SOS1 | KRAS-driven cancers (lung, pancreatic, colorectal) | Active modeling | In Screening |
| Wnt / β-catenin | Colorectal cancer, TNBC, AML | Active modeling | In Screening |
| BRD4 / MED1 | NUT carcinoma; transcription-driven cancers | Interface mapping | In Characterization |
| c-MYC / MAX dimerization | MYC amplification; broad tumor types | Interface mapping | In Characterization |
| STAT3 SH2 domain | Inflammatory cancers, glioblastoma | Scoping | Coming Q3 2026 |
Target Selection
Why These Targets
Strong Biology
- Each target has clinical genetic validation — mutations or amplifications observed across patient tumor samples
- Resistance mechanisms documented in clinical and preclinical literature
- No approved PPI disruptor covering the specific interface in our catalog
- Unmet need is biological, not just commercial: patients with these drivers lack targeted options
Favorable Interface Geometry
- Hot-spot density ≥ 3 high-ΔΔG residues per interface — sufficient sub-pocket anchoring
- Interface buried surface area in tractable range (600–2,000 Ų)
- Sub-pocket volume ≥ 200 ų identified by sitepoint analysis
- At least one known prototype disruptor in literature — structural hypothesis grounded in precedent
Target Not on the List?
Genolux accepts custom PPI target characterization engagements. If your discovery team has a priority interface not in our current catalog, contact us to discuss a scoping study.
Discuss a Custom Target